A Study of YL242 in Subjects With Advanced Solid Tumors

计划入组 424 人 · 首次发布于 2025 年 9 月 29 日

Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.

计划入组 248 人 · 首次发布于 2021 年 1 月 28 日

Treatment of Metastatic Cancer in Terminally Diagnosed Patients

首次发布于 2022 年 8 月 8 日

ML247

ML142

ML248

Neosil, Inc.

United States

Nepal Mediciti Hospital

Nepal

Laboratorios Zepol S.A.

Costa Rica

Spleen-Targeted mRNA Vaccine Shows Promise Against Hepatocellular Carcinoma in Preclinical Studies

Regeneron's Veopoz and Ordspono Show Promise in PNH and Lymphoma

Medical Student in Nepal Behind International Research Factory Exposed, Preprints Withdrawn